Nasal Drug Delivery Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Dosage Form (Nasal Spray, Nasal Drops, Nasal Ointment, Others), By Application (Disease Treatment, Research/Academic purposes), And By Geography - Forecasts From 2019 to 2024

The nasal drug delivery market is projected to grow at a CAGR of 6.58% to reach US$76.083 billion by 2024, from US$51.917 billion in 2018. Nasal drug delivery is referred to the transfer of drugs into the human body through an intranasal route of administration. These are in high demand owing to the convenience of administration in addition to providing improved patient compliance. Also, there are certain drugs that are not suitable for oral or parenteral administration, thus, calling for the need for nasal drug delivery systems. Furthermore, rising R&D investment, and growing health expenditure are driving the growth of the global nasal drug delivery market in the forecast period.

DRIVERS

Non-suitability of certain drugs via the oral or parenteral route of administration.

Increasing health expenditure worldwide.

RESTRAINTS

Stringent regulations regarding the approval of drugs and medical devices.

INDUSTRY UPDATE

On February 4, 2019, Optinose announced that it has entered into a license agreement with Inexia where Inexia has obtained certain rights which will enable the utilization of the Optinose Exhalation Delivery Systems (EDS) and other intellectual property for the discovery and development of novel therapies.

On June 12, 2017, Nemera entered into a partnership with the Research Center for Respiratory Diseases (CEPR) of Tours University in order to increase the drug's therapeutic effectiveness in the nasal cavity. The partnership is for the development of a new method of nasal administration.

The major players profiled in the nasal drug delivery market include OptiNose, Inc., Korten Pharmaceuticals Pvt. Ltd., Catalent, Inc, Cipla Inc., and Perrigo Company plc.

Nasal Drug Delivery Market Scope:

Report Metric	Details
Market size value in 2018	US$51.917 billion
Market size value in 2024	US$76.083 billion
Growth Rate	CAGR of 6.58% from 2018 to 2024
Base year	2018
Forecast period	2019–2024
Forecast Unit (Value)	USD Billion
Segments covered	Dosage Form, Application, And Geography
Regions covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies covered	OptiNose, Inc., Korten Pharmaceuticals Pvt. Ltd., Catalent, Inc, Cipla Inc., Perrigo   Company plc
Customization scope	Free report customization with purchase

 

Segmentation

The nasal drug delivery market has been analyzed through the following segments:

By Dosage Form

Nasal Spray

Nasal Drops

Nasal Ointment

Others

 

By Application

Disease Treatment

Research/Academic purposes

 

By Geography

North America

USA

Canada

Mexico

 

South America

Brazil

Argentina

Others

 

Europe

United Kingdom

Germany

France

Others

 

Middle East and Africa

Saudi Arabia

UAE

Israel

Others

 

Asia Pacific

China

India

Australia

South Korea

Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY 

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. NASAL DRUG DELIVERY  MARKET BY DOSAGE FORM

5.1. Nasal Spray

5.2. Nasal Drops

5.3. Nasal Ointment

5.4. Others

6. NASAL DRUG DELIVERY  MARKET BY APPLICATION

6.1. Disease Treatment

6.2. Research/Academic purposes

7. NASAL DRUG DELIVERY  MARKET BY GEOGRAPHY

7.1. North America

7.1.1. USA

7.1.2. Canada

7.1.3. Mexico

7.2. South America

7.2.1. Brazil

7.2.2. Argentina

7.2.3. Others

7.3. Europe

7.3.1. United Kingdom

7.3.2. Germany

7.3.3. France

7.3.4. Others

7.4. Middle East and Africa

7.4.1. Saudi Arabia

7.4.2. UAE

7.4.3. Israel

7.4.4. Others

7.5. Asia Pacific

7.5.1. China

7.5.2. India

7.5.3. Australia

7.5.4. South Korea

7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Company Benchmarking and Analysis

8.2. Recent Investment and Deals

8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. OptiNose, Inc.

9.2. Korten Pharmaceuticals Pvt. Ltd.

9.3. Catalent, Inc

9.4. Cipla Inc.

9.5. Perrigo Company plc

LIST OF FIGURES

LIST OF TABLES

OptiNose, Inc.

Korten Pharmaceuticals Pvt. Ltd.

Catalent, Inc

Cipla Inc.

Perrigo Company plc